Literature DB >> 26047796

Current and next generation influenza vaccines: Formulation and production strategies.

Peter C Soema1, Ronald Kompier2, Jean-Pierre Amorij3, Gideon F A Kersten1.   

Abstract

Vaccination is the most effective method to prevent influenza infection. However, current influenza vaccines have several limitations. Relatively long production times, limited vaccine capacity, moderate efficacy in certain populations and lack of cross-reactivity are important issues that need to be addressed. We give an overview of the current status and novel developments in the landscape of influenza vaccines from an interdisciplinary point of view. The feasibility of novel vaccine concepts not only depends on immunological or clinical outcomes, but also depends on biotechnological aspects, such as formulation and production methods, which are frequently overlooked. Furthermore, the next generation of influenza vaccines is addressed, which hopefully will bring cross-reactive influenza vaccines. These developments indicate that an exciting future lies ahead in the influenza vaccine field.
Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Influenza vaccine limitations; Influenza vaccines; Novel influenza vaccines; Universal influenza vaccine; Vaccine formulation; Vaccine production

Mesh:

Substances:

Year:  2015        PMID: 26047796     DOI: 10.1016/j.ejpb.2015.05.023

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  102 in total

1.  The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B Viruses.

Authors:  Jeremy C Jones; Bindumadhav M Marathe; Peter Vogel; Rodolfo Gasser; Isabel Najera; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Flagellin-expressing virus-like particles exhibit adjuvant effects on promoting IgG isotype-switched long-lasting antibody induction and protection of influenza vaccines in CD4-deficient mice.

Authors:  Eun-Ju Ko; Youri Lee; Young-Tae Lee; Yu-Jin Jung; Vu L Ngo; Min-Chul Kim; Ki-Hye Kim; Bao-Zhong Wang; Andrew T Gewirtz; Sang-Moo Kang
Journal:  Vaccine       Date:  2019-05-14       Impact factor: 3.641

3.  Heterologous viral protein interactions within licensed seasonal influenza virus vaccines.

Authors:  Marina Koroleva; Frances Batarse; Savannah Moritzky; Carole Henry; Francisco Chaves; Patrick Wilson; Florian Krammer; Katherine Richards; Andrea J Sant
Journal:  NPJ Vaccines       Date:  2020-01-10       Impact factor: 7.344

4.  M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection.

Authors:  D G Eliasson; A Omokanye; K Schön; U A Wenzel; V Bernasconi; M Bemark; A Kolpe; K El Bakkouri; T Ysenbaert; L Deng; W Fiers; X Saelens; N Lycke
Journal:  Mucosal Immunol       Date:  2017-03-01       Impact factor: 7.313

5.  Biological sex affects vaccine efficacy and protection against influenza in mice.

Authors:  Ashley L Fink; Kyrra Engle; Rebecca L Ursin; Wan-Yee Tang; Sabra L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-19       Impact factor: 11.205

6.  Evaluation of multivalent H2 influenza pandemic vaccines in mice.

Authors:  Brian J Lenny; Stephanie Sonnberg; Angela F Danner; Kimberly Friedman; Richard J Webby; Robert G Webster; Jeremy C Jones
Journal:  Vaccine       Date:  2017-02-08       Impact factor: 3.641

7.  Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry.

Authors:  Esteban Cruz; Joel Cain; Ben Crossett; Veysel Kayser
Journal:  Hum Vaccin Immunother       Date:  2017-11-17       Impact factor: 3.452

Review 8.  Development of a Universal Influenza Vaccine.

Authors:  Leonardo D Estrada; Stacey Schultz-Cherry
Journal:  J Immunol       Date:  2019-01-15       Impact factor: 5.422

9.  Impact of Protein Glycosylation on the Design of Viral Vaccines.

Authors:  Kathleen Schön; Bernd Lepenies; Guillaume Goyette-Desjardins
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

10.  The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4+ T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway.

Authors:  Sonia Jain; Parakkal Jovvian George; Wanyan Deng; Joseph Koussa; Kaela Parkhouse; Scott E Hensley; Jiu Jiang; Jie Lu; Zhuyun Liu; Junfei Wei; Bin Zhan; Maria Elena Bottazzi; Hao Shen; Sara Lustigman
Journal:  Vaccine       Date:  2018-06-14       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.